

Chapter 9: Mumps

Nakia Clemmons, MPH; Carole Hickman, PhD; Adria Lee, MSPH; Mona Marin, MD; Manisha Patel, MD, MS

I. Disease Description

Mumps is an acute viral illness caused by a paramyxovirus. The classic symptom of mumps is parotitis (i.e., acute onset of unilateral or bilateral tender, self-limited swelling of the parotid or other salivary gland[s]), lasting at least 2 days, but may persist longer than 10 days.¹ The mumps incubation period ranges from 12–25 days, but parotitis typically develops 16 to 18 days after exposure to mumps virus.² Nonspecific prodromal symptoms may precede parotitis by several days, including low-grade fever which may last 3–4 days, myalgia, anorexia, malaise, and headache. However, mumps infection may present only with nonspecific or primarily respiratory symptoms or may be a subclinical infection.³

Clinical manifestations

In the prevaccine era, rates of classical parotitis among all age groups typically ranged from 31% to 65%, but in specific age groups could be as low as 9% or as high as 94% depending on the age and immunity of the group.^{4–7} Several articles discuss mumps symptoms as nonspecific or primarily respiratory; however, findings in these articles were based on results of serologic specimens once every 6 months or once per year, so it is difficult to prove that the respiratory symptoms resulted from mumps or that the symptoms occurred at the same time as the mumps infection.^{6,7} In the prevaccine era, 15%–27% of infections were asymptomatic.^{4–6} In the postvaccine era, it is difficult to estimate the number of asymptomatic infections, because it is unclear how vaccine modifies clinical presentation. Serious complications can occur in the absence of parotitis.^{8,9}

Prevaccine era complications

In the prevaccine era, mumps gained notoriety as an illness that substantially affected armies during mobilization.¹ The average annual rate of hospitalization resulting from mumps during World War I was 55.8 per 1,000, which was exceeded only by the rates for influenza and gonorrhea.¹ Mumps caused transient deafness in 4.1% of infected adult males in a military population.¹⁰ Permanent unilateral deafness caused by mumps occurred in 1 of 20,000 infected persons;¹¹ bilateral, severe hearing loss was very rare.¹¹ Before the introduction of the live attenuated mumps vaccine in 1967, mumps accounted for approximately 10% of cases of aseptic meningitis in the United States with men afflicted 3 times as often as women.¹² Mumps encephalitis accounted for 35.9% of all reported encephalitis cases in the United States in 1967.¹³ The incidence of mumps encephalitis is reported to range from 1 in 6,000 mumps cases (0.02%)¹⁴ to 1 in 300 mumps cases (0.3%).¹³ Orchitis has been reported in 11.6% to 66% of postpubertal males infected with mumps.^{15,16} In 60% to 83% of males with mumps orchitis, only one testis was affected.^{4,9} Sterility from mumps orchitis, even bilateral orchitis, has rarely been reported.¹⁵ Oophoritis was reported in approximately 5% of postpubertal females affected with mumps.^{17,18} Mastitis, which had been reported in a few case reports^{19,20} was described in an outbreak in 1956–1957 as affecting 31% of postpubertal females.⁴ Pancreatitis was reported in 3.5% of persons infected with mumps in 1 community during a 2-year period⁶ and was described in case reports.^{21,22} Permanent sequelae such as paralysis, seizures, cranial nerve palsies, and hydrocephalus occurred very rarely.²³ Death due to mumps is exceedingly rare, and is primarily caused by mumps-associated encephalitis.¹³ In the United States during 1966–1971, there were 2 deaths per 10,000 reported mumps cases.¹³

Postvaccine era complications

Results from several outbreak investigations showed that hospitalizations and overall complications are lower in 2-dose vaccinated case-patients compared with unvaccinated individuals.^{24–27} Among vaccinated persons, severe complications of mumps are uncommon but occur more frequently among adults than children. In recent U.S. outbreaks in 2006 and 2009–2010, rates of orchitis among postpubertal males have



ranged from 3.3% to 10%;^{25–27} among postpubertal females, mastitis and oophoritis rates have both ranged from <1% to 1%.^{25–27} Among all persons infected with mumps, reported rates of pancreatitis, deafness, meningitis, and encephalitis were all <1%.^{25–27} No mumps-related deaths have been reported in recent U.S. outbreaks.

Mumps during pregnancy

An association between maternal mumps infection during the first trimester of pregnancy and an increase in the rate of spontaneous abortion or intrauterine fetal death has been reported in a large prospective controlled cohort study,²⁸ but this association was not found in another study.²⁹ One study with methodological limitations showed that congenital malformations may occur from mumps during pregnancy, but because the author did not compare rates with infants born to women not affected with mumps, these findings must be interpreted with caution;³⁰ other papers have not reported similar findings.^{4, 31}

Infectious period

Mumps virus is transmitted person to person through direct contact with saliva or respiratory droplets of a person infected with mumps. Although mumps virus has been isolated from 7 days before through 11–14 days after parotitis onset,^{7, 32, 33} the highest percentage of positive isolations and the highest virus loads occur closest to parotitis onset and decrease rapidly thereafter. Mumps is therefore most infectious in the several days before and after parotitis onset. Most transmission likely occurs before and within 5 days of parotitis onset.³² Transmission also likely occurs from persons with asymptomatic infections and from persons with prodromal symptoms.³⁴ In 2008, the period of isolation for mumps patients was changed from 9 days to 5 days.^{32, 33} The recommended period for contact tracing for mumps is 2 days before through 5 days after parotitis onset.

Other parotitis etiologies

Not all cases of parotitis—especially sporadic ones—are due to mumps infection. Parotitis can be caused by parainfluenza virus types 1 and 3, Epstein Barr virus, influenza A virus, Coxsackie A virus, echovirus, lymphocytic choriomeningitis virus, human immunodeficiency virus, and noninfectious causes such as drugs, tumors, immunologic diseases, and obstruction of the salivary duct. However, other causes do not produce parotitis on an epidemic scale.^{35, 36}

II. Background

Mumps vaccine was licensed in the United States in 1967. The Advisory Committee on Immunization Practices (ACIP) made a recommendation in 1977 for 1 dose of mumps vaccine for all children at any age after 12 months.³⁷ In 1989, children began receiving 2 doses of mumps vaccine because of implementation of a 2-dose measles vaccination policy using the combined measles, mumps, and rubella vaccine (MMR).³⁸ In 2006, a 2-dose mumps vaccine policy was recommended routinely for school-aged children, students at post high school educational institutions, healthcare personnel, and international travelers; 2 doses should be considered in outbreak settings for children 1–4 years of age and for adults previously vaccinated with 1 dose.³⁹

Following mumps vaccine licensure, reported cases of mumps steadily decreased from more than 152,000 reported cases in 1968 to 2,982 in 1985.⁴⁰ During 1986–1987, a resurgence occurred with more than 20,000 reported mumps cases. The primary cause of this resurgence was low vaccination levels among adolescents and young adults.⁴⁰ In the late 1980s and early 1990s, outbreaks were reported among primary and secondary school children who had previously received 1 dose of mumps-containing vaccine.^{41, 42} By 2003, only 231 mumps cases were reported, the lowest annual number since reporting began. However, in 2006, another resurgence occurred, with 6,584 reported cases.²⁵ The incidence was highest among persons 18–24 years of age, many of whom were college students. Approximately 63% of all case-patients with known vaccination status in the main outbreak states had received 2 doses of MMR vaccine.²⁵ In 2007 and 2008, the number of annual cases declined to 800 and 454 cases, respectively.

Between June 28, 2009, and June 27, 2010, another large outbreak (3,502 mumps cases) occurred in Orthodox Jewish communities in the Northeast. The median age of persons with mumps was 15 years (range: 3 months to 90 years); 2,479 (71%) were male; and of the 2,519 (72%) for whom vaccination status was reported, 76% had received 2 doses.²⁶

From December 9, 2009, through December 31, 2010, the U.S. Territory of Guam also experienced an outbreak, with 505 mumps cases reported; the median age was 12 years with a range of 2 months to 79 years.²⁷ Of the 287 school-aged children 6–18 years of age with reported mumps, 270 (94%) had received at least 2 doses of MMR vaccine. Two-dose MMR vaccine coverage in the most highly affected schools ranged from 99.3% to 100%.²⁷

In the Northeast and Guam mumps outbreaks, third doses of MMR vaccine, under Institutional Review Board protocols, were administered to the most affected populations.^{27,43} In both studies, the attack rates among those vaccinated with 3 doses of MMR were lower than among those vaccinated with 2 doses; statistical significance was not established. One study that assessed community attack rates found declines in attack rates that were more pronounced in the age groups targeted for the intervention; however, due to late timing of the intervention and other factors, the results are inconclusive as to whether the decrease was due to the intervention. Other locations experiencing mumps outbreaks during the same time frame among similar populations also showed a decline in attack rates without the third dose intervention (New York City, unpublished data).

Between July 2010 and December 2015, at least 23 large outbreaks (defined as ≥ 20 cases), consisting of 20–485 cases per outbreak were reported in 18 states. Eighteen of these outbreaks involved universities; 16 were primarily among young adults with a median age of 18 to 24 years. Of the 23 outbreaks, 9 occurred in highly vaccinated populations where 85% or more of the people affected had documentation of 2 doses of MMR vaccine. Standard intervention measures (isolation of infected individuals and age appropriate catch-up vaccinations) were instituted.⁴⁴

In 2016, a third resurgence began with 6,366 mumps cases reported, the highest number of cases since 2006; more than two-thirds of cases were outbreak-associated with outbreaks occurring in 32 jurisdictions. To better characterize the burden of outbreaks nationally, CDC invited jurisdictions to submit aggregate-level outbreak data from January 1, 2016, through June 30, 2017. This data call captured 150 outbreaks in 39 jurisdictions, consisting of 3–2,942 cases per outbreak. Seventy-five (50%) of these outbreaks occurred in universities. Fifty percent of outbreaks consisted of less than 10 cases but 20 (13%) outbreaks had 50 or more cases and accounted for 83% of the total case count. Fifty-five percent of all case-patients ($n=9,200$) and 70% of case-patients with known vaccination history ($n=7,187$) had 2 doses of MMR vaccine prior to infection. Similar to other outbreaks in the postvaccine era, the proportion of complications was low, with 270 complications occurring among 9,200 case-patients.⁴⁵

A third study, in which a third dose of MMR vaccine was administered to highly vaccinated college students during a mumps outbreak in 2015–2016, found a lower attack rate for mumps in students who received a third dose of MMR compared with students who had two doses and an increased risk for mumps with increased time since the second dose of MMR. Receipt of a third dose of MMR was associated with a 78% lower risk for mumps than receipt of two doses of MMR (95% confidence interval: 61%–88%).⁴⁶

In October 2017, ACIP recommended a third dose of a mumps-containing vaccine for persons previously vaccinated with 2 doses of a mumps-containing vaccine who are identified by public health as at increased risk for mumps because of an outbreak to improve protection against mumps and its complications (see Section XI. Outbreak Control). Worldwide, mumps is not as well controlled as measles and rubella; mumps vaccine is only routinely used in 62% of countries in the world.⁴⁷ Mumps outbreaks have also been reported among populations with high 2-dose MMR coverage in other countries.

III. Disease Reduction Goals

The 338 reported cases of mumps in 2000 met the *Healthy People 2000* reduction goal of fewer than 500 cases. Subsequently, a goal of elimination of indigenous mumps by the year 2010 was made.⁴⁸ However, major resurgences in mumps during 2006, 2009, and 2010 highlighted the challenges of obtaining this goal with currently available vaccines and the existing vaccination policy, resulting in re-evaluation of the mumps program goal in the United States. Mumps is endemic throughout the world, and achieving elimination was considered difficult in the context of potential for ongoing mumps virus importations and the current 2-dose vaccination program. Subsequently, the *Healthy People 2020* target for mumps is a disease reduction goal (i.e., to have fewer than 500 reported cases of mumps annually), rather than an

elimination goal.⁴⁹ The *Healthy People 2020* target has not been met since 2013; during this time more than half of the reported mumps cases were associated with outbreaks.

Vaccination

Live attenuated mumps virus vaccine is incorporated into combined MMR vaccine. Monovalent mumps vaccine is no longer available in the United States. For prevention of mumps, 2 doses of MMR vaccine are recommended routinely for children with the first dose at 12–15 months of age and the second dose at 4–6 years of age (school entry).^{39, 50}

Two doses of MMR vaccine are also recommended for prevention of mumps in adults at high risk, including international travelers, college and other post high school students, and healthcare personnel born during or after 1957.³⁹ All other adults born during or after 1957 without other evidence of mumps immunity should be vaccinated with 1 dose of MMR vaccine.³⁹ Vaccination recommendations for an outbreak setting, including use of a third dose of MMR vaccine, are discussed in the “Outbreak Control” section later in this chapter.

The mumps vaccine component of the MMR vaccine has a lower effectiveness compared to the measles and rubella components. Mumps vaccine effectiveness has been estimated at a median of 78% (range: 49%–91%) for 1 dose^{1, 42, 51–53} and a median of 88% (range: 66%–95%) for 2 doses.^{34, 53}

Mumps vaccine can also be administered as a combined vaccine with measles, rubella, and varicella vaccines (MMRV);⁵⁴ MMRV vaccine can be used for children 12 months through 12 years of age who need either the first or the second dose of MMR vaccine.⁵⁴ For the first dose of measles, mumps, rubella, and varicella vaccines at 12–47 months of age, either MMR vaccine and varicella vaccine or MMRV vaccine may be used. Providers who are considering administering MMRV vaccine should discuss the benefits and risks of both vaccination options with the parents or caregivers. Use of the combined MMRV vaccine entails 1 fewer injection than when MMR and varicella vaccinations are given separately. However, MMRV is associated with a higher risk for fever and febrile seizures 5–12 days after the first dose among children 12 through 23 months of age (about 1 extra febrile seizure for every 2,300–2,600 MMRV vaccine doses). Unless the parent or caregiver expresses a preference for MMRV vaccine, CDC recommends that MMR vaccine and varicella vaccine be administered for the first dose in this age group.⁵⁴ For the first dose of measles, mumps, rubella, and varicella vaccines at ages 48 months and older and for dose 2 at any age (15 months through 12 years of age), use of MMRV vaccine generally is preferred over separate injections of its equivalent component vaccines (i.e., MMR and varicella vaccines).

IV. Presumptive Evidence of Mumps Immunity

According to ACIP recommendations published in 2013,³⁹ acceptable presumptive evidence of mumps immunity includes at least 1 of the following:

- written documentation of receipt of 1 dose of a mumps-containing vaccine administered on or after the first birthday for preschool-aged children and adults not at high risk, and 2 doses of mumps-containing vaccine for school-aged children and adults at high risk (i.e., healthcare personnel, international travelers, and students at post high school educational institutions);
- laboratory evidence of immunity;
- laboratory confirmation of disease; or
- birth before 1957.

Persons who do not meet the above criteria are considered susceptible.³⁹ Healthcare settings have slightly different criteria for acceptable presumptive evidence of immunity, and these criteria are detailed in the “Healthcare personnel: presumptive evidence of immunity” section below.

V. Case Definition

The following case definition for mumps was updated and approved by the Council of State and Territorial Epidemiologists in 2011.⁵⁵

Disease-specific data elements:

Disease-specific data elements to be included in the initial report are listed below.

Clinical presentation

- Parotitis or swelling of sublingual or submandibular salivary glands for 2 or more days
- Onset date of symptoms
- Mumps-associated complications

Epidemiological evidence

- Contact (or in a chain of contacts) of a laboratory-confirmed mumps case
- Contact of a person with parotitis
- Contact of a person with a mumps-associated complication
- Member of a risk group defined by public health authorities during an outbreak
- Return from domestic or international travel within 25 days of symptom onset
- Travel location
- Date of return to state or U.S.

Immunization history

- Number of doses of mumps-containing vaccine received
- Date of all doses of mumps-containing vaccine received

Case definition for case classification

Suspect:

- Parotitis, acute salivary gland swelling, orchitis, or oophoritis unexplained by another more likely diagnosis,
or
- A positive lab result with no mumps clinical symptoms (with or without epidemiological linkage to a confirmed or probable case).

Probable:

- Acute parotitis or other salivary gland swelling lasting at least 2 days, or orchitis or oophoritis unexplained by another more likely diagnosis, in:
 - a person with a positive test for serum anti-mumps IgM antibody, or
 - a person with epidemiologic linkage to another probable or confirmed case or linkage to a group/community defined by public health during an outbreak of mumps.

Confirmed:

- A positive mumps laboratory confirmation for mumps virus with RT-PCR or culture in a patient with an acute illness characterized by any of the following:
 - acute parotitis or other salivary gland swelling, lasting at least 2 days
 - aseptic meningitis
 - encephalitis
 - hearing loss
 - orchitis
 - oophoritis

- mastitis
- pancreatitis

Case classification for import status

Internationally imported case: An internationally imported case is defined as a case in which mumps results from exposure to mumps virus outside the United States as evidenced by at least some of the exposure period (12–25 days before onset of parotitis or other mumps-associated complications) occurring outside the United States and the onset of parotitis or other mumps-associated complications within 25 days of entering the United States and no known exposure to mumps in the U.S. during that time. All other cases are considered US-acquired cases.

US-acquired case: A US-acquired case is defined as a case in which the patient had not been outside the United States during the 25 days before onset of parotitis or other mumps-associated complications or was known to have been exposed to mumps within the United States.

States may also choose to classify cases as “out-of-state-imported” when imported from another state in the United States. For national reporting, however, cases will be classified as either internationally imported or US-acquired.

VI. Laboratory Testing

If mumps is suspected, laboratory testing should be performed. Acute mumps infection can be confirmed by detection of virus by real-time RT-PCR (rRT-PCR) or by positive mumps virus culture. The presence of serum mumps immunoglobulin M (IgM), a significant rise in immunoglobulin G (IgG) antibody titer in acute- and convalescent-phase serum specimens, and IgG seroconversion, can also be used to aid in the diagnosis of mumps infection. However, in both unvaccinated and previously vaccinated persons, false-positive serologic results can occur because assays may be affected by other diagnostic entities that cause parotitis. Furthermore, laboratory confirmation of mumps in highly vaccinated populations may be challenging, and serologic tests should be interpreted with caution because false-negative results in vaccinated persons (i.e., a negative serologic test in a person with true mumps) are common. With previous contact with mumps virus either through vaccination (particularly with 2 doses) or natural infection, serum mumps IgM test results may be negative; IgG test results may be positive and elevated at the initial blood draw, making detection of a 4-fold rise unlikely; and, viral detection in RT-PCR or culture may have low yield if the buccal swab is collected more than 3 days after parotitis onset. Therefore, mumps cases should not be ruled out by negative laboratory results. These challenges are discussed in more detail below.

Virus detection (rRT-PCR and culture)

Mumps virus can be detected from fluid collected from the parotid duct (Stensen’s duct), other affected salivary gland ducts, the throat, from urine, and from cerebrospinal fluid (CSF). Parotid duct swabs yield the best viral sample, when parotitis is present. This is particularly true when the salivary gland area is massaged approximately 30 seconds prior to swabbing the buccal mucosa/parotid duct, so that the specimen contains the secretions from the parotid or other salivary duct glands. Efforts should be made to obtain the specimen as soon as possible after onset of parotitis or meningitis. Ideally, clinical specimens should be obtained within 3 days and not more than 8 days after parotitis onset.

Urine samples are less likely than oral specimens to contain sufficient virus copies or virus-infected cells for culture or detection by molecular methods, and therefore are not preferred as specimens from cases with parotitis. However, in patients presenting with mumps complications, such as orchitis or meningitis, specimens such as urine or CSF may be useful for diagnosis in addition to oral specimens.

Successful virus isolation should always be confirmed by immunofluorescence with a mumps-specific monoclonal antibody or by molecular techniques. Molecular techniques such as rRT-PCR can also be used to detect mumps RNA directly for mumps confirmation in appropriately collected specimens.

Molecular typing is recommended because it provides important epidemiologic information. Molecular

epidemiologic surveillance (i.e., virus genotyping) allows the building of a sequence database that will help track transmission pathways of mumps strains circulating in the United States. In addition, genotyping methods are available to distinguish wild-type mumps virus from vaccine virus.

- **Unvaccinated persons:** Virus may be isolated from the parotid duct/buccal mucosa until 11–14 days after salivary enlargement; however, viral isolation is most likely to be successful just prior to and within the first 3 days of parotitis onset.
- **Vaccinated persons:** In order to optimize virus yield, emphasis should be placed on obtaining mumps clinical specimens from buccal mucosa within 1 to 3 days after onset of symptoms (usually parotitis).

For specimens being submitted for virus culture or RT-PCR assay, immediately place specimens in a cold storage container and transport to the laboratory.

Serologic testing

The serologic tests available to aid in the diagnosis of acute mumps infection and confirmation of previous exposure to mumps vary among laboratories. The state health department can provide guidance regarding available laboratory services. At the direction of the state health department, healthcare providers and state and local health departments may send serum specimens from suspected mumps cases to CDC's Measles, Mumps, Rubella, and Herpes Laboratory Branch for IgM detection using a capture IgM enzyme immunoassay (EIA; non-quantitative) that incorporates a recombinant mumps nucleocapsid protein as the antigen. See the "Specimen collection and management" section below.

Tests for IgM antibody

- **EIA:** a highly specific test for diagnosing acute mumps infection. The use of the IgM capture EIA is preferred over the immunofluorescence assay (IFA).
- **IFA:** a test that is relatively inexpensive and simple, but the IFA format is particularly susceptible to interference by high levels of mumps-specific IgG. Reading the test requires considerable skill and experience since this nonspecific staining may cause false-positive readings if the serum is not treated with an agent to remove human IgG antibody.

Note: Commercially available EIA kits and IFA antibody assays for detection of mumps IgM are currently not approved by the Food and Drug Administration for this use. Therefore, each laboratory must validate these tests independently.

Serum collection and timing of the mumps IgM response

- **Unvaccinated persons:** IgM antibody is detectable within 5 days after onset of symptoms, reaches a maximum level about a week after onset, and remains elevated for several weeks or months.^{56,57} If an acute-phase serum sample collected ≤ 3 days after parotitis onset is negative for IgM, testing a second sample collected 5–7 days after symptom onset is recommended as the IgM response may require more time to develop.
- **Vaccinated persons:** Patients that mount a secondary immune response to mumps, as seen in most previously vaccinated persons, may not have an IgM response, or it may be transient and not detected depending on the timing of specimen collection.⁵⁶ Because of this, a high number of false-negative results may occur in previously vaccinated individuals. False-positive IgM results may also occur and appear to be more prevalent with certain IgM test formats, such as the IFA. Collecting specimens >3 days after parotitis onset improves the ability to detect IgM among persons that were previously vaccinated. Of serum samples collected from outbreaks less than 3 days after symptom onset 13–46% were positive compared to 71% of serum samples collected >3 days.^{58–61} However, persons with a history of mumps vaccination may not have detectable mumps IgM antibody regardless of the timing of specimen collection.

Tests for IgG antibody

Tests for IgG antibody: may be used for mumps diagnosis or for determining prior exposure to mumps vaccine or mumps virus. A variety of tests for IgG antibodies to mumps are available and include EIA, IFA, and plaque reduction neutralization. The specific criteria for documenting the presence of antibody or an increase in titer depends on the test. Older persons or persons with no history of mumps illness or vaccination may have detectable mumps IgG due to a previous subclinical infection.

Diagnosis of mumps with IgG: a single serum sample tested for mumps-specific IgG is not useful for diagnosing acute mumps infection. Documentation of seroconversion from negative to positive or a 4-fold rise in IgG titer using paired specimens as measured in plaque-reduction neutralization assays or similar quantitative assays can be used to aid in the diagnosis of mumps. Tests for IgG antibody should be conducted on both acute- and convalescent-phase specimens at the same time, and the same type of test should be used on both specimens. EIA values are not titers, and increases in EIA values do not directly correspond to rises in titer results.

- **Unvaccinated persons:** In unvaccinated persons, IgG antibody increases rapidly after onset of symptoms and is long lasting.
- **Vaccinated persons:** In vaccinated persons, the IgG may already be quite elevated in the acute-phase blood sample, which frequently prevents detection of a 4-fold rise in IgG titer in the convalescent serum specimen. For this reason, detection of a 4-fold rise in IgG is not recommended for use among previously vaccinated persons.

Presumptive laboratory evidence of immunity

The presence of mumps-specific IgG, as detected using a serologic assay (EIA or IFA), is considered evidence of prior exposure to mumps vaccine or mumps virus but does not necessarily predict the presence of neutralizing antibodies or protection from mumps disease.

Specimen collection and management

Specimen collection and shipping are important steps in obtaining laboratory diagnosis or disease confirmation. Guidelines have been published for specimen collection and handling for viral and microbiologic agents. Information is also available on using CDC laboratories as support for reference and disease surveillance; this includes

- a central website (<https://www.cdc.gov/laboratory/specimen-submission/index.html>) for requesting lab testing;
- the form (<https://www.cdc.gov/laboratory/specimen-submission/pdf/form-50-34.pdf>) required for submitting specimens to CDC (See Appendix 23, Form # CDC 0.5034);
- information on general requirements for shipment of etiologic agents (Appendix 24, <https://www.cdc.gov/vaccines/pubs/surv-manual/appx/appendix24-etiological-agent.pdf>)—although written to guide specimen submission to CDC, this information may be applicable to submission of specimens to other laboratories; and
- the CDC Infectious Diseases Laboratories Test Directory (<https://www.cdc.gov/laboratory/specimen-submission/list.html>), which contains not only a list of orderable tests for that institution, but also detailed information on appropriate specimen types, collection methods, specimen volume, and points of contact.

Specific instructions for specimen collection and shipping may be obtained from the CDC mumps website (<https://www.cdc.gov/mumps/lab/specimen-collect.html>) or by contacting the CDC Viral Vaccine Preventable Diseases Branch at 404-639-3339. Specimens for RT-PCR, virus isolation, and genotyping should be sent to CDC as directed by the State Health Department.

For additional information on use of laboratory testing for surveillance of vaccine-preventable diseases, see Chapter 22, “Laboratory Support for the Surveillance of Vaccine-Preventable Diseases.”

VII. Reporting and Case Notification

Case reporting within a jurisdiction

Each state and U.S. territory has regulations or laws governing the reporting of diseases and conditions of public health importance.⁶² These regulations and laws list the diseases that are to be reported and describe those persons or groups responsible for reporting, such as healthcare providers, hospitals, schools, laboratories, daycare and childcare facilities, and other institutions. Persons reporting these conditions should contact their State Health Department for state-specific reporting requirements.

Case notification to CDC

Provisional notifications of all probable and confirmed mumps cases should be sent by the State Health Department to CDC using eventcode 10180 via the National Notifiable Diseases Surveillance System (NNDSS). Electronic reporting of case records should not be delayed because of incomplete information or lack of confirmation. Following completion of case investigations, case records should be updated with any new information and resubmitted to CDC. Final laboratory results may not be available for the initial report but should be submitted via NNDSS when available. The state in which the patient resides at the time of diagnosis should submit the case notification to CDC. For further inquiries, please email: ncirddvdmmrhp@cdc.gov

Information to collect

The following data should be collected in the course of the case investigation. Additional information may be collected at the direction of the State Health Department.

● **Demographic information**

- Name
- Address
- Date of birth
- Age
- Sex
- Ethnicity
- Race
- Country of birth
- Length of time in United States
- Reporting source
- County
- Earliest date reported

● **Clinical information**

- Date of illness onset (note: this may be earlier than parotitis onset due to prodromal symptoms)
- Parotitis or other salivary gland involvement (pain, tenderness, swelling)
- Date of parotitis (or other salivary gland swelling) onset
- Duration of parotitis (or other salivary gland swelling)
- Other symptoms (e.g., headache, anorexia, fatigue, fever, body aches, stiff neck, difficulty in swallowing, nasal congestion, cough, earache, sore throat, nausea, abdominal pain)

● **Complications**

- Deafness (transient or permanent; unilateral or bilateral)
- Encephalitis
- Mastitis
- Meningitis
- Oophoritis
- Orchitis (unilateral or bilateral)
- Pancreatitis
- Other

- **Hospitalization**
 - Outcome (patient survived or died)
 - Date of death
 - Postmortem examination results
 - Death certificate diagnoses
 - Reason/association to mumps
 - Duration of stay
- **Treatment**
 - Medications given
 - Duration person was on each medication
- **Laboratory**
 - Serology (IgM, IgG)
 - Virus detection (PCR, culture)
 - Specimen collection date(s)
- **Vaccine information**
 - Number of doses of vaccine given
 - Type of vaccine administered (i.e., MMR, MMRV, or single antigen mumps vaccine)
 - Dates of mumps vaccination for each dose
 - Manufacturer of vaccine
 - Vaccine lot number
 - If not vaccinated, reason
- **Epidemiologic**
 - Epidemiologic linkages
 - Transmission setting (e.g., college, school, doctor's office)
 - Import status (e.g., internationally imported or US-acquired). See Case Classification section above.
 - Location of exposure (country, if international import; state, if out-of-state import)
 - Travel history

VIII. Case Investigation

The Mumps Surveillance Worksheet (Appendix 10) may be used as a guideline to collect case information during a case investigation; the details are discussed below.

Case identification

Identification of suspected or confirmed cases of mumps is important in the initiation of control measures to prevent the spread of the disease among persons who do not have presumptive evidence of immunity. Once a sporadic case has been identified, several factors should be considered before initiating a public health response, such as epidemiological risk factors, vaccination status, and other etiologies. However, in transmission settings with high risk, such as households, schools, and camps, health departments may want to be more proactive. In these settings, health departments should consider conducting case investigations and assessing immune status of close contacts before laboratory results are known or before additional cases are identified. Implementation of control measures may be contingent on setting, likelihood of ongoing transmission, and available resources.

Establishing a diagnosis of mumps

Clinical diagnosis of mumps may be unreliable. Cases of suspected mumps should be laboratory confirmed; however, negative laboratory results among vaccinated persons do not necessarily rule out the diagnosis of mumps, particularly if there is an outbreak of parotitis. Efforts should be made to obtain clinical specimens (buccal cavity/parotid duct fluids, throat swabs, or serum; urine can be collected for cases of orchitis or CSF collected for meningitis or encephalitis) for molecular detection and/or serologic testing from all sporadic cases and at least some cases in each outbreak at the time of the initial investigation. For sporadic cases that have negative laboratory results for mumps, consider testing for other etiologies such as influenza virus, Epstein Barr virus, adenovirus, parainfluenza viruses types 1, 2, and 3.

Obtaining accurate, complete immunization histories

Mumps case investigations should include complete immunization histories verified by documentation of administration of all doses. Verbal history of receipt of mumps vaccine is not considered adequate proof of vaccination. Some case-patients or their caregivers may have personal copies of immunization records available that include dates of administration—these are acceptable for reporting purposes.

Identifying the source of infection

Efforts should be made to identify the source of infection for every confirmed case of mumps (i.e., case-patients should be asked about contact with other known patients). However, this is not always possible, especially with sporadic cases, and this should not occur at the expense of higher public health priorities. If it can be determined when and where transmission likely occurred, investigative efforts should be directed to these locations.

Assessing potential transmission and identifying contacts

The potential for further transmission should be assessed. Contacts of the case-patient during the 2 days prior through 5 days after onset of parotitis should be identified, assessed for immunity, offered vaccine as appropriate, and educated about signs and symptoms.

CDC recommends a 5-day period after onset of parotitis for: 1) isolation of persons with mumps in the community and for 2) use of droplet precautions, in addition to standard precautions in healthcare settings.³²

IX. Enhancing Surveillance

Importance of surveillance

Information obtained through surveillance is used to follow disease trends in the population, to assess progress towards disease reduction goals, and to characterize populations requiring additional disease control measures.

Monitoring surveillance indicators

Regular monitoring of surveillance indicators can help identify specific areas of the surveillance and reporting system that need improvement. The following indicators should be monitored.

- The proportion of confirmed cases reported to NNDSS with complete information (e.g., date of birth, onset date, clinical case definition, hospitalization, laboratory testing, vaccine history, date reported to health department, transmission setting, outbreak-related, and epidemiologic linkage)
- The interval between date of symptom onset and date of public health notification
- The proportion of cases that are laboratory confirmed
- The proportion of cases that have an imported source

The activities listed below can help increase the number of suspected mumps cases that are reported and improve the comprehensiveness and quality of reports that are received. Additional guidelines for enhancing surveillance are given in Chapter 19, “Enhancing Surveillance.”

Promoting awareness

In the event of an outbreak, surveillance should be enhanced by promoting awareness in the community affected by the outbreak and among healthcare personnel. Healthcare personnel should be aware that mumps outbreaks have occurred in highly vaccinated populations in high transmission settings, including

school settings (e.g., elementary school, middle school, high school, and college students). Therefore, mumps should not be ruled out on the assumption that individuals have evidence of mumps immunity because of vaccination.

X. Outbreak Investigation

A mumps outbreak is defined as 3 or more cases linked by time and place. In recent years, mumps outbreaks have occurred in highly vaccinated populations in high transmission settings, including elementary, middle, and high schools, colleges, and camps. Especially in these settings, rapid detection and investigation of cases, and implementation of control measures may reduce the magnitude of outbreaks.⁵³ The following are general guidelines for an outbreak investigation.

Collecting tracking information

During an outbreak, a line listing of cases on a spreadsheet allows for quick identification of known and unknown data and ensures for complete case investigations.

Identifying the population affected by the outbreak

During an outbreak, every suspected case should be investigated, as described above. In very large outbreaks, it may not be possible to thoroughly investigate each reported case.

Based on the findings of individual case investigations, the population affected by the outbreak should be characterized in terms of:

- person (who is becoming infected with mumps, what is their vaccination status),
- place (where are the cases), and
- time (when did the outbreak start, and is it still going on).

These essential data elements allow public health officials to determine the population at risk of infection (e.g., unvaccinated persons, students who have only received 1 dose of mumps vaccine, persons who visited the emergency department of Hospital A on a certain day, highly vaccinated populations in high transmission settings); to determine where transmission is occurring (e.g., schools, colleges, healthcare settings); and to identify individuals who are at potential risk of infection (e.g., other unvaccinated persons, students attending other schools).

Obtaining accurate and complete immunization histories

Vaccination histories may be obtained from schools (generally available for children attending licensed childcare centers or kindergarten through high school, as well as many universities), medical providers, or immunization records provided by the case-patient. Immunization registries, if available, can also readily provide vaccination histories.

Investigating contacts

Identifying contacts (e.g., household, school/college, and other close contacts) and following up with persons without evidence of mumps immunity may reveal previously undiagnosed and unreported cases.

Enhancing surveillance for mumps

Local or state health departments should contact healthcare providers in outbreak areas to inform them of the outbreak and request reporting of any suspected cases. During outbreaks, active surveillance for mumps should be conducted for every confirmed and probable mumps case. Active surveillance should be maintained for at least 2 incubation periods (50 days) following parotitis onset in the last case. Two incubation periods allow for the identification of transmission from subclinical infections or unrecognized cases. Previously unreported cases may be identified by reviewing laboratory records.

XI. Outbreak Control

Initial preparation for control activities may need to start before laboratory results are known.

The main strategy for controlling a mumps outbreak is to define the population(s) at risk and transmission setting(s), and to rapidly identify and vaccinate persons without presumptive evidence of immunity; or, if a

contraindication exists, to consider excluding persons without presumptive evidence of immunity from the setting to prevent exposure and transmission. The ACIP reviewed the available evidence and determined that a third dose of MMR was safe and effective at preventing mumps and its complications in persons at increased risk because of an outbreak and recommended for its use in October 2017.

Mumps-containing vaccine should be administered to persons without evidence of immunity and everyone should be brought up to date with age appropriate vaccination (1 or 2 doses). In an outbreak setting, persons previously vaccinated with 1 or 2 doses of a mumps-containing vaccine and who are identified by public health as at increased risk for mumps because of the outbreak should receive a dose of a mumps-containing vaccine (second dose for persons previously vaccinated with 1 dose or a third dose for persons previously vaccinated with 2 doses) to improve protection against mumps and its complications. Although mumps-containing vaccination has not been shown to be effective in preventing mumps in persons already infected, it will prevent infection in those persons who are not yet exposed or infected. If persons without evidence of immunity can be vaccinated early in the course of an outbreak, they can be protected prior to exposure. However, because of the long incubation period for mumps, cases are expected to continue to occur for at least 25 days among newly vaccinated persons who may have been infected before vaccination.⁶³ As with all vaccines, some individuals will not develop protective immunity after receipt of mumps vaccine.

Exclusion of susceptible persons during outbreaks in schools and colleges until the 26th day after parotitis onset in the last person with mumps at the affected school may decrease risk of infection in these individuals; complications may also be decreased by decreasing risk of disease. Exclusion from schools/colleges affected by a mumps outbreak or other schools that are unaffected but deemed by local public health authorities to be at risk for transmission of disease should be considered for students with zero doses of MMR vaccine and with no other evidence of mumps immunity, including students with exemptions for medical, religious, or other reasons. Considerations for recommending exclusion include increased risk of complications in susceptible persons or contribution of unvaccinated persons to ongoing transmission. Excluded students can be readmitted immediately after they are vaccinated. Students who have a history of 1 dose of MMR vaccination should be allowed to remain in school and recommended to receive their second vaccine dose.

Evidence is limited and insufficient at this time to fully characterize the impact of a third dose of a mumps-containing vaccine on reducing the size and duration of mumps outbreaks; studies are ongoing to address this question. CDC is currently updating guidance for use of a third dose of a mumps-containing vaccine during mumps outbreaks. Persons at increased risk for mumps are those who are more likely to be exposed to respiratory droplets or saliva of a mumps case-patient, such as through close contact with infected persons or sharing of drinks or utensils. Public health should consider several factors in identifying defined groups at increased risk for mumps during an outbreak, including:

1. number and distribution of cases
2. intense exposure settings likely to facilitate transmission (e.g., schools, colleges, correctional facilities, congregate living facilities)
3. site(s) of ongoing transmission
4. place of residence during the outbreak
5. intensity and duration of close contact
6. social networks.

Once groups at increased risk are identified, persons in these groups may be advised to seek vaccine through routine channels or through designated clinics; the recommendation of a third dose by public health does not obligate the use of publicly financed vaccine or a vaccination campaign.

Catch-up vaccination efforts to ensure that populations at risk are up to date with the recommended number of vaccine doses, including a third dose for persons identified by public health as at increased risk because of a mumps outbreak, as well as reducing opportunities for close contact, are recommended strategies during mumps outbreaks.

XII. Healthcare Settings

Prevention and control strategies in healthcare settings

Prevention and control strategies should be applied in all healthcare settings, including outpatient and long-term care facilities. These measures include:

- assessment of presumptive evidence of immunity of healthcare personnel, including documented administration of 2 doses of live mumps virus vaccine, laboratory evidence of immunity or laboratory confirmation of disease, or birth before 1957 (refer to next section, “Healthcare personnel: presumptive evidence of immunity” for footnotes);
- vaccination of those without evidence of immunity;
- exclusion of healthcare personnel with active mumps illness, as well as healthcare personnel who do not have presumptive evidence of immunity who are exposed to persons with mumps;
- isolation of patients in whom mumps is suspected; and
- implementation of droplet precautions, in addition to standard precautions.

An effective vaccination program is the best approach to prevent healthcare-associated mumps transmission. Healthcare Infection Control Practices Advisory Committee (HICPAC) and CDC have recommended that secure, preferably computerized, systems should be used to manage vaccination records for healthcare personnel so records can be easily retrieved as needed.⁶⁴ Facilities are also encouraged to review employee evidence of immunity status for mumps and other vaccine preventable infections. Healthcare facilities should provide MMR vaccine to all personnel without evidence of mumps immunity at no charge.

Healthcare personnel: presumptive evidence of immunity

The presumptive evidence of immunity criteria for healthcare personnel differs slightly from the criteria for community settings. The following criteria should be followed to assess presumptive evidence of immunity among healthcare personnel.⁶⁵

- Written documentation of vaccination with 2 doses of live mumps or MMR vaccine administered at least 28 days apart*
- Laboratory evidence of immunity[†]
- Laboratory confirmation of disease
- Birth before 1957^{‡§¶}

* The first dose of mumps-containing vaccine should be administered on or after the first birthday; the second dose should be administered no earlier than 28 days after the first dose.

† Mumps immunoglobulin (IgG) in the serum; equivocal results should be considered negative.

‡ May vary depending on current state or local requirements.

§ For unvaccinated personnel born before 1957 who lack laboratory evidence of mumps immunity or laboratory confirmation of disease, healthcare facilities should consider vaccinating personnel with two doses of MMR vaccine at the appropriate interval.

¶ For unvaccinated personnel born before 1957 who lack laboratory evidence of mumps immunity or laboratory confirmation of disease, healthcare facilities should recommend two doses of MMR vaccine during an outbreak of mumps.

Mumps outbreaks among vaccinated healthcare personnel are rare and when they do occur, are usually quickly contained. In the event that a nosocomial outbreak occurs, healthcare facilities should have a plan in place for the implementation of the 2-dose recommendation for all healthcare personnel, including those who were born before 1957 and lack laboratory evidence of immunity or laboratory confirmation of disease. Healthcare facilities may choose to proceed with appropriate assessment and vaccination of personnel born before 1957 before an outbreak occurs.

Although there are no data that correlate levels of serum antibody with protection from disease, presence of mumps-specific IgG antibodies is considered evidence of mumps immunity. For healthcare personnel who do not have adequate presumptive evidence of mumps immunity, prevaccination antibody screening before MMR vaccination is not necessary.

Results of serum antibody tests in vaccinated persons are difficult to interpret. In vaccinated persons, antibody levels are often lower than following natural infection, and commercially available tests may not detect such low levels of antibody. As a result, postvaccination serologic testing to verify an immune response to MMR or its component vaccines is not recommended.

Management of healthcare personnel with illness due to mumps

A diagnosis of mumps should be considered in exposed healthcare personnel who develop non-specific respiratory infection symptoms during the incubation period after unprotected exposures to mumps, even in the absence of parotitis.

Healthcare personnel with mumps illness should be excluded for 5 days after the onset of parotitis.

Management of healthcare personnel who are exposed to persons with mumps

Unprotected exposures are defined as being within 3 feet of a patient with a diagnosis of mumps without the use of proper personal protective equipment. Irrespective of their immune status, all exposed healthcare personnel should report any signs or symptoms of illness during the incubation period, from 12 through 25 days after exposure.

For healthcare personnel who do not have acceptable presumptive evidence of immunity: Healthcare personnel without evidence of immunity should be excluded from the 12th day after the first unprotected exposure to mumps through the 25th day after the last exposure. Previously unvaccinated healthcare personnel who receive a first dose of vaccine after an exposure are considered non-immune and should be excluded from the 12th day after the first exposure to mumps through the 25th day after the last exposure. The mumps vaccine cannot be used to prevent the development of mumps after exposure.

For healthcare personnel with partial vaccination: Healthcare personnel who had been previously vaccinated for mumps, but received only 1 dose of mumps vaccine may continue working following an unprotected exposure to mumps. Such personnel should receive a second dose as soon as possible, but no sooner than 28 days after the first dose. They should be educated about symptoms of mumps, including nonspecific presentations, and should notify occupational health if they develop these symptoms.

For healthcare personnel who have presumptive evidence of immunity: Healthcare personnel with evidence of immunity do not need to be excluded from work following an unprotected exposure. However, 2 doses of MMR vaccine do not provide 100% protection from mumps. Some vaccinated personnel may remain at risk for mumps and steps should be taken to reduce the risk of infection. Therefore, healthcare personnel should be educated about symptoms of mumps, including nonspecific presentations, and should notify occupational health if they develop these symptoms.

References

1. Plotkin SA, Rubin SA. Mumps vaccine. In: Plotkin S, Orenstein W, Offit P, editors. *Vaccines*. Philadelphia, PA: Saunders; 2008. p. 435–65.
2. American Academy of Pediatrics. Mumps. In: Pickering LK, et al, editors. *Red Book: 2009 report of the Committee on Infectious Diseases*. Elk Grove Village, IL: American Academy of Pediatrics; 2009. p. 468–72.
3. Hviid A, Rubin S, Muhlemann K. Mumps. *Lancet* 2008;371(9616):932–44. doi: 10.1016/S0140-6736(08)60419-5
4. Philip RN, Reinhard KR, Lackman DB. Observations on a mumps epidemic in a virgin population. *Am J Hyg* 1959;69(2):91–111.
5. Reed D, Brown G, Merrick R, Sever J, Feltz E. A mumps epidemic on St. George Island, Alaska. *JAMA* 1967; 199(13):113–7. doi: 10.1001/jama.1967.03120130053007
6. Falk WA, Buchan K, Dow M, et al. The epidemiology of mumps in southern Alberta, 1980–1982. *Am J Epidemiol* 1989;130(4):736–49. doi: 10.1093/oxfordjournals.aje.a115395
7. Cooney MK, Fox JP, Hall CE. The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and *Mycoplasma pneumoniae*. *Am J Epidemiol* 1975;101(6):532–51. doi: 10.1093/oxfordjournals.aje.a112125

8. Johnstone JA, Ross CA, Dunn M. Meningitis and encephalitis associated with mumps infection. A 10-year survey. *Arch Dis Child* 1972;47(254):647–51. doi: 10.1136/adc.47.254.647
9. Beard CM, Benson RC Jr, Kelalis PP, Elveback LR, Kurland LT. The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974. *Mayo Clin Proc* 1977;52(1):3–7.
10. Vuori M, Lahikainen EA, Peltonen T. Perceptive deafness in connection with mumps: a study of 298 servicemen suffering from mumps. *Acta Otolaryngol* 1962;55:231–6. doi: 10.3109/00016486209127357
11. Everberg G. Deafness following mumps. *Acta Otolaryngol* 1957;48(5-6):397–403. doi: 10.3109/00016485709126900
12. Litman N, Baum SG. Mumps virus. In: Mandell GL, Bennett JE, and Dolin R, editors. *Mandell, Douglas, and Bennett's principles and practice of infectious diseases*. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010. p. 2201–06.
13. CDC. Mumps surveillance: January 1972–June 1974. Atlanta, GA: U.S. Department of Health, Education, and Welfare, Public Health Service; 1974.
14. Russell RR, Donald JC. The neurological complications of mumps. *Br Med J* 1958;2(5087):27–30.
15. Werner CA. Mumps orchitis and testicular atrophy; occurrence. *Ann Intern Med* 1950;32(6):1066–74. doi: 10.7326/0003-4819-32-6-1066
16. Rambar AC. Mumps: use of convalescent serum in the treatment and prophylaxis of orchitis. *Am J Dis Child* 1946;71:1–13. doi: 10.1001/archpedi.1946.02020240008001
17. Morrison JC, Givens, JR, Wisner WL, Fish SA. Mumps oophoritis: a cause of premature menopause. *Fertil Steril* 1975;26(7):655–9.
18. Taparelli F, Squadrini F, De Rienzo B, Lami G, Fornaciari A. Isolation of mumps virus from vaginal secretions in association with oophoritis. *J Infect* 1988;17(3):255–8. doi: 10.1016/S0163-4453(88)96618-2
19. Weaver RJ, Petry TN. Mumps mastitis in the nursing female, with a case report. *J Indiana State Med Assoc* 1958;51(5):644–5.
20. Lee CM. Primary virus mastitis from mumps. *Va Med Mon* (1918) 1946;73:327.
21. Witte CL, Schanzer B. Pancreatitis due to mumps. *JAMA* 1968;203(12):1068–9. doi: 10.1001/jama.1968.03140120066019
22. Veghelyi PV. Secondary pancreatitis. *Am J Dis Child* 1947;74(1):45–51.
23. Gibbons JL, Miller HG, Stanton JB. Parainfectious encephalomyelitis and related syndromes; a critical review of neurological complications of certain specific fevers. *Q J Med* 1956;25(100):427–505.
24. Barskey AE, Schulte C, Rosen JB, et al. Mumps outbreak among Orthodox Jewish communities in the United States. *N Engl J Med* 2012;367(18):1704–13. doi: 10.1056/NEJMoa1202865.
25. Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States. *N Engl J Med* 2008;358(15):1580–9. doi: 10.1056/NEJMoa0706589
26. CDC. Update: mumps outbreak—New York and New Jersey, June 2009–January 2010. *MMWR Morb Mortal Wkly Rep* 2010;59(5):125–9. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5905a1.htm>
27. Nelson G, Aguon AL, Valencia E, Oliva R, Guerrero ML, Reyes R, et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control—Guam 2009 to 2010. *Pediatr Infect Dis J* 2013;32(4):374–80.
28. Siegel M, Fuerst HT, Peress NS. Comparative fetal mortality in maternal virus diseases. A prospective study on rubella, measles, mumps, chicken pox and hepatitis. *N Engl J Med* 1966;274(14):768–71. doi: 10.1056/NEJM196604072741404
29. Enders M, Rist B, Enders G. [Frequency of spontaneous abortion and premature birth after acute mumps infection in pregnancy]. *Gynakol Geburtshilfliche Rundsch* 2005;45(1):39–43. doi: 10.1159/000081715
30. Bowers D. Mumps during pregnancy. *West J Surg Obstet Gynecol* 1953;61(2):72–3.
31. Siegel M. Congenital malformations following chickenpox, measles, mumps, and hepatitis. Results of a cohort study. *JAMA* 1973;226(13):1521–4. doi: 10.1001/jama.1973.03230130009003

32. Kutty PK, Kyaw MH, Dayan GH, et al. Guidance for isolation precautions for mumps in the United States: a review of the scientific basis for policy change. *Clin Infect Dis* 2010;50(12):1619–28. doi: 10.1086/652770
33. CDC. Updated recommendations for isolation of persons with mumps. *MMWR Morb Mortal Wkly Rep* 2008;57(40):1103–5.
34. Marin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, Lebaron CW. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students—Iowa, 2006. *Vaccine* 2008;26(29–30):3601–7. doi: 10.1016/j.vaccine.2008.04.075
35. Davidkin I, Jokinen S, Paananen A, Leinikki P, Peltola H. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. *J Infect Dis* 2005;191(5):719–23. doi: 10.1086/427338
36. Gershon A. Mumps. In: Fauci A, Braunwald E, Kasper DL, editors. *Harrison's principles of internal medicine*. 17th ed. New York, NY: McGraw-Hill p. 1220–22.
37. CDC. Mumps vaccine: Recommendation of Public Health Service Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep* 1977;26(48):393–4.
38. CDC. Measles prevention. *MMWR Morb Mortal Wkly Rep* 1989;38(Suppl 9):1–18. <https://www.cdc.gov/mmwr/preview/mmwrhtml/00041753.htm>
39. CDC. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2013;62(RR-04):1–34. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm?s_cid=rr6204a1_w
40. CDC. Current trends mumps—United States, 1985–1988. *MMWR Morb Mortal Wkly Rep* 1989;38(7):101–5. <https://www.cdc.gov/mmwr/preview/mmwrhtml/00001351.htm>
41. Briss PA, Fehrs LJ, Parker RA, et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. *J Infect Dis* 1994;169(1):77–82. doi: 10.1093/infdis/169.1.77
42. Hersh BS, Fine PE, Kent WK, et al. Mumps outbreak in a highly vaccinated population. *J Pediatr* 1991;119(2):187–93. doi: 10.1016/S0022-3476(05)80726-7
43. Ogbuanu IU, Kutty PK, Hudson JM, et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. *Pediatrics* 2012;130(6): e1567–74. doi: 10.1542/peds.2012-0177
44. Clemmons NS, Marin M, Routh J, Patel M. Mumps: July 2010–2015, 2016 and beyond. Presented at: 47th National Immunization Conference; 2016 Sept 14; Atlanta, GA.
45. Clemmons NS, Lee AD, Lopez A, Marin M, Marlow M, Patel M. Reported mumps cases (Jan 2011–Jun 2017) and outbreaks (Jan 2016–Jun 2017) in the United States. ID Week 2017; 10/5/2017; San Diego, CA2017.
46. Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M, et al. Effectiveness of a third dose of mmr vaccine for mumps outbreak control. *NEJM* 2017;377(10):947–56. doi: 10.1056/NEJMoal703309
47. WHO. Immunization coverage fact sheet. Geneva: World Health Organization [update 2017 July; cited 2017 October 4]. <http://www.who.int/mediacentre/factsheets/fs378/en/>
48. U.S. Department of Health and Human Services. Healthy people 2010: understanding and improving health. Washington, DC: Department of Health and Human Services; 2000. <http://www.healthypeople.gov/2010/>
49. U.S. Department of Health and Human Services. Healthy people 2020. Washington, DC: Department of Health and Human Services; 2010. <https://www.healthypeople.gov/>
50. CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 1998;47(RR-8):1–57. <https://www.cdc.gov/mmwr/preview/mmwrhtml/00053391.htm>
51. Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. *Bull World Health Organ* 1999;77(1):3–14.

52. Cheek JE, Baron R, Atlas H, Wilson DL, Crider RD J. Mumps outbreak in a highly vaccinated school population. Evidence for large-scale vaccination failure. *Arch Pediatr Adolesc Med* 1995;149(7):774–8. doi: 10.1001/archpedi.1995.02170200064010
53. Schaffzin JK, Pollock L, Schulte C, et al. Effectiveness of previous mumps vaccination during a summer camp outbreak. *Pediatrics* 2007;120(4):e862–8. doi: 10.1542/peds.2006-3451
54. CDC. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2010;59(RR-3):1–12.
55. CSTE. Public health reporting and national notification for mumps. CSTE position statement 11-ID-18. Atlanta, GA: CSTE; 2011. <http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/PS/11-ID-18.pdf>
56. Ukkonen P, Granstrom ML, Penttinen K. Mumps-specific immunoglobulin M and G antibodies in natural mumps infection as measured by enzyme-linked immunosorbent assay. *J Med Virol* 1981;8(2):131–42. doi: 10.1002/jmv.1890080207
57. Benito RJ, Larrad L, Lasierra MP, Benito JF, Erdociaín F. Persistence of specific IgM antibodies after natural mumps infection. *J Infect Dis* 1987;155(1):156–7. doi: 10.1093/infdis/155.1.156
58. Krause CH, Molyneaux PJ, Ho-Yen DO, McIntyre P, Carman WF, Templeton KE. Comparison of mumps-IgM ELISAs in acute infection. *J Clin Virol* 2007;38(2):153–6. doi: 10.1016/j.jcv.2006.10.010
59. CDC. Mumps. materials and methods for specimen collection, storage, and shipment. Atlanta, GA: CDC. [updated 2016 November 17; cited 2017 October 4]. <https://www.cdc.gov/mumps/lab/specimen-collect.html>
60. Bitsko RH, Cortese MM, Dayan GH, Rota PA, Lowe L, Iversen SC, Bellini WJ. Detection of RNA of mumps virus during an outbreak in a population with a high level of measles, mumps, and rubella vaccine coverage. *J Clin Microbiol* 2008;46(3):1101-3. doi: 10.1128/JCM.01803-07
61. Rota JS, Rosen JB, Doll MK, et al. Comparison of the sensitivity of laboratory diagnostic methods from a well-characterized outbreak of mumps in New York City in 2009. *Clin Vaccine Immunol* 2013;20(3):391–6. doi: 10.1128/CVI.00660-12.
62. Roush S, Birkhead G, Koo D, Cobb A, Fleming D. Mandatory reporting of diseases and conditions by health care professionals and laboratories. *JAMA* 1999;282(2):164–70. doi: 10.1001/jama.282.2.164
63. Wharton M, Cochi SL, Hutcheson RH, Bistowish JM, Schaffner W. A large outbreak of mumps in the postvaccine era. *J Infect Dis* 1988;158(6):1253–60. doi: 10.1093/infdis/158.6.1253
64. Bolyard EA, Tablan OC, Williams WW, et al. Guideline for infection control in healthcare personnel, 1998. *Infect Control Hosp Epidemiol* 1998;19(6):407–63. doi: 10.2307/30142429
65. CDC. Immunization of health-care personnel. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2011;60(RR-7):1–45. <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6007a1.htm>